Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment

This publication has 21 references indexed in Scilit:

• Risk–benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting
  Expert Opinion on Drug Safety, 2004
• Randomized, Double-Blind, Dose-Finding Study of Dexamethasone in Preventing Acute Emesis Induced by Anthracyclines, Carboplatin, or Cyclophosphamide:
  Journal of Clinical Oncology, 2004
• The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group
  Journal of Clinical Oncology, 2003
• Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics
  British Journal of Cancer, 2003
• Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting
  Cancer, 2003
• Establishing the dose of the oral NK₁ antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting
  Cancer, 2003
• Antiemetic guidelines: creating a more practical treatment approach
  Supportive Care in Cancer, 2002
• Delayed emesis: incidence, pattern, prognostic factors and optimal treatment
  Supportive Care in Cancer, 2002
• How do we manage patients with refractory or breakthrough emesis?
  Supportive Care in Cancer, 2002
• Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial
  Cancer, 1987